Comment on this story

0 Comments on this story



Post comments

Email to a friend




Send email

Related Jobs

Lilly withdraws Cymbalta application

01 Dec 2008

Regulatory Affairs

Eli Lilly has withdrawn a supplemental new drug application for Cymbalta in the US.

The application it made to the Food and Drug Administration (FDA) related to the extended use of the drug as a therapy for chronic pain and did not affect its status as a treatment in other indications.

Lilly will resubmit the application in the first half of 2009, this time including additional data from a clinical study which was recently completed.

According to the firm, the new trial results are from a study of patients with chronic osteoarthritis in the knee.

"This was a difficult decision but we believe the updated data package will give the FDA a broader basis for reviewing our application," said John Hayes, a vice-president at Lilly Research Laboratories.

Lilly recently completed the acquisition of ImClone Systems, which has now become a wholly-owned subsidiary of the company.

John Lechleiter, Lilly's president and chief executive officer, pointed out that the move gives his firm's oncology pipeline a boost.


Bookmark and Share

0 comments on this story